These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 24725538)

  • 1. Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy.
    Robinson GW; Orr BA; Gajjar A
    BMC Cancer; 2014 Apr; 14():258. PubMed ID: 24725538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation.
    Kim KB; Cabanillas ME; Lazar AJ; Williams MD; Sanders DL; Ilagan JL; Nolop K; Lee RJ; Sherman SI
    Thyroid; 2013 Oct; 23(10):1277-83. PubMed ID: 23489023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
    Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
    Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequency of BRAF V600E mutations in 969 central nervous system neoplasms.
    Behling F; Barrantes-Freer A; Skardelly M; Nieser M; Christians A; Stockhammer F; Rohde V; Tatagiba M; Hartmann C; Stadelmann C; Schittenhelm J
    Diagn Pathol; 2016 Jun; 11(1):55. PubMed ID: 27350555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NICE guidance on vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma.
    Perampaladas K; Hay N; Rinaldi F; Robertson J; Adam J
    Lancet Oncol; 2013 Jan; 14(1):20-1. PubMed ID: 23401870
    [No Abstract]   [Full Text] [Related]  

  • 6. BRAF Inhibition in
    Kaley T; Touat M; Subbiah V; Hollebecque A; Rodon J; Lockhart AC; Keedy V; Bielle F; Hofheinz RD; Joly F; Blay JY; Chau I; Puzanov I; Raje NS; Wolf J; DeAngelis LM; Makrutzki M; Riehl T; Pitcher B; Baselga J; Hyman DM
    J Clin Oncol; 2018 Dec; 36(35):3477-3484. PubMed ID: 30351999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of mutated, activated BRAF in metastatic melanoma.
    Flaherty KT; Puzanov I; Kim KB; Ribas A; McArthur GA; Sosman JA; O'Dwyer PJ; Lee RJ; Grippo JF; Nolop K; Chapman PB
    N Engl J Med; 2010 Aug; 363(9):809-19. PubMed ID: 20818844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib.
    Maleka A; Åström G; Byström P; Ullenhag GJ
    BMC Cancer; 2016 Aug; 16():634. PubMed ID: 27520988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.
    Tiacci E; Park JH; De Carolis L; Chung SS; Broccoli A; Scott S; Zaja F; Devlin S; Pulsoni A; Chung YR; Cimminiello M; Kim E; Rossi D; Stone RM; Motta G; Saven A; Varettoni M; Altman JK; Anastasia A; Grever MR; Ambrosetti A; Rai KR; Fraticelli V; Lacouture ME; Carella AM; Levine RL; Leoni P; Rambaldi A; Falzetti F; Ascani S; Capponi M; Martelli MP; Park CY; Pileri SA; Rosen N; Foà R; Berger MF; Zinzani PL; Abdel-Wahab O; Falini B; Tallman MS
    N Engl J Med; 2015 Oct; 373(18):1733-47. PubMed ID: 26352686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autophagy inhibition improves chemosensitivity in BRAF(V600E) brain tumors.
    Levy JM; Thompson JC; Griesinger AM; Amani V; Donson AM; Birks DK; Morgan MJ; Mirsky DM; Handler MH; Foreman NK; Thorburn A
    Cancer Discov; 2014 Jul; 4(7):773-80. PubMed ID: 24823863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
    Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
    Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful (neo)adjuvant BRAF-targeted therapy in a patient with locally advanced BRAF V600E mutant melanoma.
    Seremet T; Lienard D; Suppa M; Trepant AL; Rorive S; Woff E; Cuylits N; Jansen Y; Schreuer M; Del Marmol V; Neyns B
    Melanoma Res; 2015 Apr; 25(2):180-3. PubMed ID: 25643238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: a retrospective case series.
    Chamberlain MC
    J Neurooncol; 2013 Sep; 114(2):237-40. PubMed ID: 23756728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.
    McArthur GA; Chapman PB; Robert C; Larkin J; Haanen JB; Dummer R; Ribas A; Hogg D; Hamid O; Ascierto PA; Garbe C; Testori A; Maio M; Lorigan P; Lebbé C; Jouary T; Schadendorf D; O'Day SJ; Kirkwood JM; Eggermont AM; Dréno B; Sosman JA; Flaherty KT; Yin M; Caro I; Cheng S; Trunzer K; Hauschild A
    Lancet Oncol; 2014 Mar; 15(3):323-32. PubMed ID: 24508103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vemurafenib treatment of BRAF V600E-mutated malignant peripheral nerve sheath tumor.
    Kaplan HG
    J Natl Compr Canc Netw; 2013 Dec; 11(12):1466-70. PubMed ID: 24335681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population Pharmacokinetics of Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E-Mutant Astrocytomas.
    Wang H; Long-Boyle J; Winger BA; Nicolaides T; Mueller S; Prados M; Ivaturi V
    J Clin Pharmacol; 2020 Sep; 60(9):1209-1219. PubMed ID: 32476174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF VE1 immunoreactivity patterns in epithelioid glioblastomas positive for BRAF V600E mutation.
    Kleinschmidt-DeMasters BK; Aisner DL; Foreman NK
    Am J Surg Pathol; 2015 Apr; 39(4):528-40. PubMed ID: 25581727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dramatic response of BRAF V600E-mutant epithelioid glioblastoma to combination therapy with BRAF and MEK inhibitor: establishment and xenograft of a cell line to predict clinical efficacy.
    Kanemaru Y; Natsumeda M; Okada M; Saito R; Kobayashi D; Eda T; Watanabe J; Saito S; Tsukamoto Y; Oishi M; Saito H; Nagahashi M; Sasaki T; Hashizume R; Aoyama H; Wakai T; Kakita A; Fujii Y
    Acta Neuropathol Commun; 2019 Jul; 7(1):119. PubMed ID: 31345255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease.
    Haroche J; Cohen-Aubart F; Emile JF; Maksud P; Drier A; Tolédano D; Barete S; Charlotte F; Cluzel P; Donadieu J; Benameur N; Grenier PA; Besnard S; Ory JP; Lifermann F; Idbaih A; Granel B; Graffin B; Hervier B; Arnaud L; Amoura Z
    J Clin Oncol; 2015 Feb; 33(5):411-8. PubMed ID: 25422482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy.
    Sloot S; Zager JS; Kudchadkar RR; Messina JL; Benedict JJ; Gonzalez RJ; DeConti R; Turner LM; McCardle T; Smalley KS; Weber JS; Sondak VK; Gibney GT
    Melanoma Res; 2016 Feb; 26(1):83-7. PubMed ID: 26731560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.